First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients ...

The following is a summary of “Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy ...

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

The proteomic landscape of muscle-invasive bladder cancer (MIBC) in the context of platinum-based neoadjuvant chemotherapy (NAC) remains to be explored. Here, proteomic analysis of MIBC tumours ...

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ: URGN), a biotech company focusing on urothelial and specialty cancer treatments with impressive gross profit margins of 90%, recently shared long-term ...

Anktiva (nogapendekin alfa inbakicep, or N-803) can be used in combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients who had not responded to the BCG shot on its ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before ...